knowledge -WSS

knowledge

author：hotspot 2025-10-01 23:38:45 - browse：486

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： FDA's Woodcock to retire early next year

focus

WSS

FDA's Woodcock to retire early next year

Does good food count as health care? Study aims to find out

FDA's Woodcock to retire early next year

What is STAT's opinion section for?

Today's health inequities arise from racist U.S. history, say experts

First transplant of an entire human eye performed

hotspot

knowledge

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

FDA's Woodcock to retire early next year

Tori Bowie and the unacceptable rates of Black maternal death

Type 2 diabetes prevention programs work at large scale: study

Psychedelics group wrestles with new pharma identity

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals look to new technology to keep health care workers safe

Dobbs anniversary: the lost opportunity of abortion as health care

UnitedHealth sued over use of algorithm in Medicare Advantage plans

focus

Does good food count as health care? Study aims to find out

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medicare’s new pay boost for primary care is angering specialists

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Why medical students are struggling with mental health

Hospitals look to new technology to keep health care workers safe

Wikipedia

focus

focus

Wikipedia